Puma Biotechnology
PBYI
158 hedge funds and large institutions have $1.33B invested in Puma Biotechnology in 2019 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 53 increasing their positions, 44 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
86% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 22
85% more capital invested
Capital invested by funds: $717M → $1.33B (+$609M)
65% more call options, than puts
Call options by funds: $33.2M | Put options by funds: $20.1M
20% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 44
12% more funds holding
Funds holding: 141 → 158 (+17)
3.48% less ownership
Funds ownership: 92.29% → 88.81% (-3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$79.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24M |
| 3 |
D.E. Shaw & Co
New York
|
+$13M |
| 4 |
FAM
Fred Alger Management
New York
|
+$11.3M |
| 5 |
Goldman Sachs
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$33.3M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$26.5M |
| 3 |
MAM
Melqart Asset Management
London,
United Kingdom
|
-$23.6M |
| 4 |
O
OrbiMed
New York
|
-$22M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$15.7M |
PBYI Hedge Fund Activity: Q1 2019 in Review
158 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2019, worth a combined $1.33B — up 85% from $717M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new PBYI positions and 22 closed out — a net gain of 19 holders — while 53 added to existing stakes and 44 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $79.5M. The largest seller was State Street, cutting an estimated $33.3M.
- 158 institutional investors held Puma Biotechnology (PBYI) as of Q1 2019, up from 141 in Q4 2018.
- Funds reported $1.33B of Puma Biotechnology stock for Q1 2019, up 85% quarter-over-quarter.
- 41 funds opened new Puma Biotechnology positions in Q1 2019 and 22 closed out, a net change of +19 holders.
- The largest Puma Biotechnology buyer in Q1 2019 was PFM Health Sciences, an estimated $79.5M added.
- The largest Puma Biotechnology seller in Q1 2019 was State Street, an estimated $33.3M sold.
Based on aggregated 13F filings for Q1 2019.